AstraZeneca unveils The Hub, a new amenities centre, on Cambridge Biomedical Campus
AstraZeneca has today officially opened The Hub in Cambridge, a purposely designed amenities centre, where employees and the local community can collaborate, socialise and unwind.
Latest H1 and Q2 2024 results for AstraZeneca
Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said:
Acquisition of Amolyt Pharma completed
AstraZeneca announces the successful completion of the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare
AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
Amolyt development portfolio includes Phase III asset with potential to address significant unmet need in patients with chronic hypoparathyroidism Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition, building on company’s succes
AstraZeneca plans £650 million investment in UK
The pharmaceutical firm's investment will boost the UK's Life Sciences sector.
Strong growth trajectory for AstraZeneca as it reports 9M and Q3 2023 results
Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said:
“Our company continued its strong growth trajectory in the third quarter with Total Revenue from our non‑COVID-19 medicines up 13% compared to last year.
AstraZeneca - Powering emissions reductions with clean heat and renewable energy
The research, development and production of medicines is an energy intensive process. As part of our transition to net zero, we have announced a series of innovative partnerships which are decarbonising our operations, expanding access to renewable energy and contributing to the circular economy. In the UK and in the US, we will use renewable natural gas (RNG), or biomethane, to supply clean heat…
AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia
Approval based on results from ASCEND global Phase III trial and a Phase I/II local trial, which showed 83.3% overall response rate in Chinese patients treated with Calquence.
AstraZeneca demonstrates scientific leadership with compelling new data at ESC Congress 2023 on the interconnections across chronic diseases
Wealth of heart failure data supports medical guideline updates and underscores commitment to improving patient outcomes.
Qureight collaborates with AstraZeneca on lung disease research
Cambridge-based data analytics company Qureight has entered into a multi-year collaboration with biopharmaceutical company AstraZeneca.
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health.
AstraZeneca full Year and Q4 2022 results
AstraZeneca publishes their full year and Q4 2022 results, with comment from Pascal Soriot, Chief Executive Officer.
AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline
The acquisition will give access to global rights to baxdrostat, a novel aldosterone synthase inhibitor in development for blood pressure lowering.
AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
Acquisition provides access to next-generation T-cell receptor therapies with promising potential for targeting solid tumours.
Q3 2022 results highlights strong performance from AstraZeneca
Latest results highlight more than $10 billion in product sales in Q3, taking the haul over $33bn in the year to date.
AstraZeneca announces Enhertu delays disease progression in DESTINY-Breast02 Phase III Trial
Results consistent with previous trials, reinforcing benefit of AstraZeneca and Daiichi Sankyo’s Enhertu in previously treated patients.
AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening its haematological cancer pipeline
AstraZeneca announces an agreement to acquire TeneoTwo, Inc., including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma1.
AstraZeneca’s Pascal Soriot awarded British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic
AstraZeneca’s Chief Executive Officer, Pascal Soriot, receives a British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic in the Queen’s Birthday Honours 2022.
AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against COVID-19
AstraZeneca enters into a licence agreement with RQ Biotechnology Ltd (RQ Bio) for a portfolio of early-stage monoclonal antibodies (mAbs) targeted against SARS-CoV-2, the virus that causes COVID-19.
AstraZeneca announces strong first quarter results
AstraZeneca posts Q1 revenue increases, highlighting total revenue for the second quarter rose 60 per cent to $11,390m, reflecting strong growth across the company.
AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts
AstraZeneca announces plans to open a new site at the heart of the Cambridge, MA, life sciences and innovation hub.
EU approves AstraZeneca Covid prevention drug - Evusheld
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg.
AstraZeneca and Scorpion agree to develop novel cancer treatments against ‘undruggable’ targets
AstraZeneca has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialise precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.
AstraZeneca unveils The Discovery Centre (DISC) in Cambridge
AstraZeneca will today, in the presence of His Royal Highness The Prince of Wales, formally unveil The Discovery Centre (DISC) in Cambridge – a state-of-the-art research and development (R&D) facility designed to the world’s highest environmental standards and accommodating over 2,200 research scientists.
AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
The first of many millions of doses of AstraZeneca’s COVID-19 vaccine have begun arriving in low and middle-income countries across the world through the multilateral COVAX initiative, the first steps in fulfilling the Company’s efforts to provide broad and equitable access to the vaccine.